Physician profile
Peter Lawrence Loo
NPI 1275828535
$1,652.54
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $47.49 · 2021: $1,155 · 2022: $161.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $887.95 | 2021-2022 | |
| Novo Nordisk INC | $194.24 | 2019-2022 | |
| Lilly USA, LLC | $152.33 | 2019-2022 | |
| Abbvie INC. | $123.89 | 2021-2022 | |
| Emmaus Medical, INC. | $37.70 | 2021 | |
| Amgen INC. | $37.53 | 2021-2022 | |
| Amarin Pharma, INC. | $30.20 | 2020-2021 | |
| Glaxosmithkline, LLC. | $27.87 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $26.63 | 2019 | |
| Integra Lifesciences Corporation | $24.06 | 2020 | |
| Astellas Pharma US INC | $22.48 | 2019 | |
| Stryker Corporation | $20.14 | 2021 | |
| Biogen, INC. | $18.16 | 2022 | |
| Wright Medical Technology, INC. | $13.43 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.27 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $12.07 | 2021 | |
| Shire North American Group INC | $11.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Loo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.